| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
REVIEW ARTICLE |
1 From the Asthma, Allergy and Immune Disorders Group, Murdoch Childrens Research Institute, Royal Children’s Hospital, Victoria, Australia (RJB and MLKT), and the Department of Microbiology and Immunology, University of Melbourne, Victoria, Australia (RMR-B)
Probiotics have been advocated for the prevention and treatment of a wide range of diseases, and there is strong evidence for their efficacy in some clinical scenarios. Probiotics are now widely used in many countries by consumers and in clinical practice. Given the increasingly widespread use of probiotics, a thorough understanding of their risks and benefits is imperative. In this article we review the safety of probiotics and discuss areas of uncertainty regarding their use. Although probiotics have an excellent overall safety record, they should be used with caution in certain patient groups—particularly neonates born prematurely or with immune deficiency. Because of the paucity of information regarding the mechanisms through which probiotics act, appropriate administrative regimens, and probiotic interactions, further investigation is needed in these areas. Finally, note that the properties of different probiotic species vary and can be strain-specific. Therefore, the effects of one probiotic strain should not be generalized to others without confirmation in separate studies. Careful consideration should be given to these issues before patients are advised to use probiotic supplements in clinical practice.
Key Words: Probiotics • sepsis • Lactobacillus • Saccharomyces
Related articles in AJCN:
This article has been cited by other articles:
|
|
 |
|
  Y. E. M. Dommels, R. A. Kemperman, Y. E. M. P. Zebregs, R. B. Draaisma, A. Jol, D. A. W. Wolvers, E. E. Vaughan, and R. Albers Survival of Lactobacillus reuteri DSM 17938 and Lactobacillus rhamnosus GG in the Human Gastrointestinal Tract with Daily Consumption of a Low-Fat Probiotic Spread Appl. Envir. Microbiol., October 1, 2009; 75(19): 6198 - 6204. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Mariam Interaction between Lactic Acid Bacteria and Mycobacterium bovis in Ethiopian Fermented Milk: Insight into the Fate of M. bovis Appl. Envir. Microbiol., March 15, 2009; 75(6): 1790 - 1792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Sherman, J. C. Ossa, and K. Johnson-Henry Unraveling Mechanisms of Action of Probiotics Nutr Clin Pract, February 1, 2009; 24(1): 10 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Imhoff and K. Karpa Is There a Future for Probiotics in Preventing Clostridium difficile-Associated Disease and Treatment of Recurrent Episodes? Nutr Clin Pract, February 1, 2009; 24(1): 15 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Rohde, V. Bartolini, and N. Jones The Use of Probiotics in the Prevention and Treatment of Antibiotic-Associated Diarrhea With Special Interest in Clostridium difficile-Associated Diarrhea Nutr Clin Pract, February 1, 2009; 24(1): 33 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Wallace Clinical Use of Probiotics in the Pediatric Population Nutr Clin Pract, February 1, 2009; 24(1): 50 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Karimi, M. D. Inman, J. Bienenstock, and P. Forsythe Lactobacillus reuteri-induced Regulatory T cells Protect against an Allergic Airway Response in Mice Am. J. Respir. Crit. Care Med., February 1, 2009; 179(3): 186 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lopez, N. Li, J. Kataria, M. Russell, and J. Neu Live and Ultraviolet-Inactivated Lactobacillus Rhamnosus GG Decrease Flagellin-Induced Interleukin-8 Production in Caco-2 Cells J. Nutr., November 1, 2008; 138(11): 2264 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Candela, G. Miccoli, S. Bergmann, S. Turroni, B. Vitali, S. Hammerschmidt, and P. Brigidi Plasminogen-dependent proteolytic activity in Bifidobacterium lactis Microbiology, August 1, 2008; 154(8): 2457 - 2462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hickson, A. L D'Souza, N. Muthu, T. R Rogers, S. Want, C. Rajkumar, and C. J Bulpitt Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial BMJ, July 14, 2007; 335(7610): 80 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Segarra-Newnham Probiotics for Clostridium difficile-Associated Diarrhea: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii Ann. Pharmacother., July 1, 2007; 41(7): 1212 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Karpa Probiotics for Clostridium difficile Diarrhea: Putting It into Perspective Ann. Pharmacother., July 1, 2007; 41(7): 1284 - 1287. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
